Denali's AVLAYAH Launch Validates Platform, But Commercial Ramp Remains Early

What happened

Denali Therapeutics has crossed the regulatory finish line with FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome, and the company reported its first commercial sales of $3.6 million in Q2 2026, with management guiding to a tripling of revenue in Q3 as patient starts and payer coverage expand. This confirms the base-case scenario from our earlier deep value assessment, which had assigned a 45% probability to tividenofusp gaining accelerated approval with modest initial uptake, though the reported revenue is at the low end of what we considered plausible for an orphan enzyme replacement therapy launch. The news validates the Transport Vehicle platform's ability to deliver a brain-penetrant enzyme, but it does not yet resolve the key uncertainties around long-term label restrictions, competitive pressure from standard-of-care Elaprase, and the durability of payer reimbursement for a premium-priced CNS-active ERT. With the stock likely trading above our previous $18.26 reference point on this news, the asymmetry between upside and downside has narrowed, and the remaining 2026 catalysts—LUMA Phase 2b data for BIIB122/DNL151 and additional TV pipeline readouts—will determine whether the platform premium can be sustained. We maintain a cautious stance: the commercial launch is encouraging but early, and the company's elevated cash burn and concentrated reliance on a single approved product argue for waiting for either a pullback toward the mid-teens or clearer evidence of durable commercial traction before adding exposure.

Implication

For current holders, the approval and initial sales validate the core thesis, but the stock's reaction may already price in a smooth launch; consider trimming into strength above $24–26, consistent with our prior trim level. For new investors, the risk/reward is less compelling at elevated prices given the remaining binary outcomes from LRRK2 and TV pipeline data, and the potential for dilution if cash burn continues; we would look to initiate only on a pullback toward $14–16, or after LUMA data de-risks the Parkinson's program. The key monitoring points are quarterly AVLAYAH revenue growth, payer coverage decisions, and any updates on the confirmatory trial design for the accelerated approval.

Thesis delta

The FDA approval and initial commercial launch of AVLAYAH shift the investment case from a purely binary regulatory event to early commercial execution, which lowers the probability of a catastrophic downside scenario but also reduces the upside optionality that existed pre-approval. Our prior base case of a modest launch with eventual low-hundreds of patients by 2028 is tracking, but the reported $3.6M Q2 revenue implies a slower start than some optimistic projections, and the stock's likely upward move compresses the margin of safety. We now view the risk/reward as more balanced, warranting a neutral-to-cautious stance unless the shares retreat to a level that prices in launch disappointment or until additional pipeline data provides a new catalyst.